Cargando…
When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest
BACKGROUND: Much like academic-industry partnerships, industry financial support of patient advocacy organizations (PAOs) has become very common in recent years. While financial conflicts of interest (FCOI) between PAOs and industry have received more attention in recent years, robust efforts to mit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918599/ https://www.ncbi.nlm.nih.gov/pubmed/31847854 http://dx.doi.org/10.1186/s12910-019-0435-1 |
_version_ | 1783480622954577920 |
---|---|
author | Ehrlich, Orna Wingate, Laura Heller, Caren de Melo-Martin, Inmaculada |
author_facet | Ehrlich, Orna Wingate, Laura Heller, Caren de Melo-Martin, Inmaculada |
author_sort | Ehrlich, Orna |
collection | PubMed |
description | BACKGROUND: Much like academic-industry partnerships, industry financial support of patient advocacy organizations (PAOs) has become very common in recent years. While financial conflicts of interest (FCOI) between PAOs and industry have received more attention in recent years, robust efforts to mitigate these conflicts are still limited. MAIN BODY: The authors outline the possible benefits and ethical concerns that can result from financial interactions between biomedical companies and PAOs. They argue that the use of novel strategies, such as the creation of a standing ethics committee, could be helpful in managing FCOIs and ensuring the warranted trust of PAO’s constituents. Although ethics committees to address FCOIs are common in the academic context, its use by PAOs is still limited. The authors conclude by describing the process of development and implementation of such an ethics committee at the Crohn’s & Colitis Foundation. CONCLUSIONS: While collaborations with industry can result in conflicts of interest, PAOs can develop strategies to address those conflicts. One such strategy is the creation of a standing independent ethics committee to guide PAOs on new and/or existing programs and protocols as they pertain to their industry relationships. |
format | Online Article Text |
id | pubmed-6918599 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69185992019-12-20 When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest Ehrlich, Orna Wingate, Laura Heller, Caren de Melo-Martin, Inmaculada BMC Med Ethics Debate BACKGROUND: Much like academic-industry partnerships, industry financial support of patient advocacy organizations (PAOs) has become very common in recent years. While financial conflicts of interest (FCOI) between PAOs and industry have received more attention in recent years, robust efforts to mitigate these conflicts are still limited. MAIN BODY: The authors outline the possible benefits and ethical concerns that can result from financial interactions between biomedical companies and PAOs. They argue that the use of novel strategies, such as the creation of a standing ethics committee, could be helpful in managing FCOIs and ensuring the warranted trust of PAO’s constituents. Although ethics committees to address FCOIs are common in the academic context, its use by PAOs is still limited. The authors conclude by describing the process of development and implementation of such an ethics committee at the Crohn’s & Colitis Foundation. CONCLUSIONS: While collaborations with industry can result in conflicts of interest, PAOs can develop strategies to address those conflicts. One such strategy is the creation of a standing independent ethics committee to guide PAOs on new and/or existing programs and protocols as they pertain to their industry relationships. BioMed Central 2019-12-17 /pmc/articles/PMC6918599/ /pubmed/31847854 http://dx.doi.org/10.1186/s12910-019-0435-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Debate Ehrlich, Orna Wingate, Laura Heller, Caren de Melo-Martin, Inmaculada When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest |
title | When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest |
title_full | When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest |
title_fullStr | When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest |
title_full_unstemmed | When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest |
title_short | When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest |
title_sort | when patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest |
topic | Debate |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918599/ https://www.ncbi.nlm.nih.gov/pubmed/31847854 http://dx.doi.org/10.1186/s12910-019-0435-1 |
work_keys_str_mv | AT ehrlichorna whenpatientadvocacyorganizationsmeetindustryanovelapproachtodealingwithfinancialconflictsofinterest AT wingatelaura whenpatientadvocacyorganizationsmeetindustryanovelapproachtodealingwithfinancialconflictsofinterest AT hellercaren whenpatientadvocacyorganizationsmeetindustryanovelapproachtodealingwithfinancialconflictsofinterest AT demelomartininmaculada whenpatientadvocacyorganizationsmeetindustryanovelapproachtodealingwithfinancialconflictsofinterest |